touchCONGRESS HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the ESMO 2019?

In this interview, Judy King answers the following questions:

• How important are the overall survival data reported for CDK4/6 inhibitors at ESMO 2019 when managing your patients with HR+/HER2- advanced breast cancer?
• Results from the subgroup analyses from the CompLEEment-1 trial were presented. In your opinion, how useful are clinical factors for predicting response to CDK4/6 inhibitors?
• In your clinic, what are the roles of nurses and other staff when managing adverse events of CDK4/6 inhibitors?
• Combining CDK4/6 inhibitors with other targeted agents, such as HER2 inhibitors, are being investigated in clinical trials. In your opinion how valuable are these findings for the future management of patients with advanced breast cancer?
• Which data stood out for you at the ESMO 2019 and why? What are their implications for clinical practice in your region?

Dr Judy King is a Consultant Medical Oncologist at the Royal Free London NHS Foundation Trust in the UK. She qualified from Cambridge University and Guys and St Thomas’ School of Medicine and Dentistry in 2001 and completed a PhD in T cell immunotherapy of malignancies in 2008. During her specialty training, she also completed a Darzi Fellowship in Leadership and Management and completed a Postgraduate Certificate from Leeds Business School.

Dr King’s main research interest is in combining chemotherapy and novel agents with immunotherapy and HER2-directed therapies. She also sits on the Joint Specialty Committee for Medical Oncology at the Royal College of Physicians and is Oncology Training Director for the Royal Free Hospital.

Dr Judy King discloses: Advisory board/consultancy fees from Eisai, Genomic Health, Lilly, Novartis, Pfizer and Roche.

In this interview, Emilio Alba answers the following questions:

• How important are the overall survival data reported for CDK4/6 inhibitors at ESMO 2019 when managing your patients with HR+/HER2- advanced breast cancer?
• Results from the subgroup analyses from the CompLEEment-1 trial were presented. In your opinion, how useful are clinical factors for predicting response to CDK4/6 inhibitors?
• In your clinic, what are the roles of nurses and other staff when managing adverse events of CDK4/6 inhibitors?
• Combining CDK4/6 inhibitors with other targeted agents, such as HER2 inhibitors, are being investigated in clinical trials. In your opinion how valuable are these findings for the future management of patients with advanced breast cancer?
• Which data stood out for you at the ESMO 2019 and why? What are their implications for clinical practice in your region?

Dr Emilio Alba is Director of the Medical Oncology Units at the Hospital Universitario Virgen de la Victoria, Malaga, Spain. He is a Professor of Oncology and Director of the Biomedical Research Centre (CIMES) at the University of Malaga and head of the scientific area in Oncology-Oncohaematology-Rare Diseases-Transplants in the Biomedical Research Institute in Malaga (IBIMA).

Dr Alba qualified from the University of Malaga in 1981 and completed his specialization in Medical Oncology in 1987. He is the author of more than 180 publications in scientific journals and has participated in numerous oral communications in national and international congresses. He has supervised 13 PhD and a number of postdoctoral projects and as the director of the CIMES he mentors and guides principal investigators in the field of molecular oncology.

Dr Emelio Alba discloses:  Advisory roles with BMS, Genomic Health, Lilly, Nanostring, Novartis, Pfizer, and Roche. Travel grants from Celgene. Investigation grants from MSD, Nanostring, Pfizer, Roche and Sysmex.

In this interview, Masahiro Takada answers the following questions:

• How important are the overall survival data reported for CDK4/6 inhibitors at ESMO 2019 when managing your patients with HR+/HER2- advanced breast cancer?
• Results from the subgroup analyses from the CompLEEment-1 trial were presented. In your opinion, how useful are clinical factors for predicting response to CDK4/6 inhibitors?
• In your clinic, what are the roles of nurses and other staff when managing adverse events of CDK4/6 inhibitors?
• Combining CDK4/6 inhibitors with other targeted agents, such as HER2 inhibitors, are being investigated in clinical trials. In your opinion how valuable are these findings for the future management of patients with advanced breast cancer?
• Which data stood out for you at the ESMO 2019 and why? What are their implications for clinical practice in your region?

Prof. Masahiro Takada is Assistant Professor at the Department of Breast Surgery, Kyoto University Hospital, Kyoto, Japan. Previously, he was a Fellow in Breast Surgery (2012), Research Fellow of the Japan Society for the Promotion of Science (2010–2012) and Research Assistant of Global COE Program ‘Center for FrontierMedicine’ by the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), Japan (2008–2010).

He qualified from the School of Medicine, Hokkaido University, Sapporo in 2001 and completed a PhD at the Graduate School of Medicine, Kyoto University in 2012.

Prof. Takada has the following board certifications: Board Certified Surgeon of the Japan Surgical Society (2007), Board Certified Breast Surgeon of the Japan Breast Cancer Society (2013), Board Certified Trainer of the Japan Breast Cancer Society (2018) and Board Certified Trainer of the Japan Surgical Society (2019).

He has contributed to over 30 publications including ten as the primary author in scientific journals for breast cancer research.

Prof. Masahiro Takada discloses:  Honoraria from AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, Kyowa-Kirin and Pfizer. Grants from AstraZeneca, Daiichi Sankyo and Eisai.

In this interview, Oliver Trédan answers the following questions

• How important are the overall survival data reported for CDK4/6 inhibitors at ESMO 2019 when managing your patients with HR+/HER2- advanced breast cancer?
• Results from the subgroup analyses from the CompLEEment-1 trial were presented. In your opinion, how useful are clinical factors for predicting response to CDK4/6 inhibitors?
• In your clinic, what are the roles of nurses and other staff when managing adverse events of CDK4/6 inhibitors?
• Combining CDK4/6 inhibitors with other targeted agents, such as HER2 inhibitors, are being investigated in clinical trials. In your opinion how valuable are these findings for the future management of patients with advanced breast cancer?
• Which data stood out for you at the ESMO 2019 and why? What are their implications for clinical practice in your region?

Dr Oliver Trédan is Medical Oncologist at the Centre Léon Bérard (Lyon, France) and Senior Researcher at Lyon University and was the Coordinator of the Teaching and Training Programme there for 5 years. He is currently the Head of the Department of Medical Oncology at the Centre Leon Bérard and leads the breast/gynaecological translational research programme. His clinical practice is devoted to breast and gynaecological cancer patients.

He is the Principal Investigator of several Phase I/II clinical trials investigating molecular screening and new targeted agents, especially for triple-negative breast cancers. Dr Trédan is the author of more than 100 publications, including publications as first or last author in Lancet Oncology, Annals of Oncology, and Journal of the National Cancer Institute.

Dr Oliver Trédan discloses:  Advisory roles for Bristol Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer and Roche.

In this interview, Valentina Guarneri answers the following questions:

• How important are the overall survival data reported for CDK4/6 inhibitors at ESMO 2019 when managing your patients with HR+/HER2- advanced breast cancer?
• Results from the subgroup analyses from the CompLEEment-1 trial were presented. In your opinion, how useful are clinical factors for predicting response to CDK4/6 inhibitors?
• In your clinic, what are the roles of nurses and other staff when managing adverse events of CDK4/6 inhibitors?
• Combining CDK4/6 inhibitors with other targeted agents, such as HER2 inhibitors, are being investigated in clinical trials. In your opinion how valuable are these findings for the future management of patients with advanced breast cancer?
• Which data stood out for you at the ESMO 2019 and why? What are their implications for clinical practice in your region?

Prof. Valentina Guarneri is the head of the Translational Research and Innovative Therapy Unit at the Istituto Oncologico Veneto IRCCS, Padua and the Vice-Director of the Specialty Programme in Medical Oncology. In addition to being a member of the Research Committee of the Italian Ministry, she is also a member of the ESMO Fellowship and Award Committee and the Oncology Pro-Working Group and a founder member of the Women for Oncology Italy initiative. She is on the editorial review board of several International journals and has more than 100 peer-reviewed publications. Her research interest is focused on clinical and translational research for breast cancer patients.

Prof. Valentina Guarneri discloses:  Advisory role for Eli Lilly. Research grant from Roche. Lecture fees from AstraZeneca, Eli Lilly and Novartis.

In this interview, Wolfgang Janni answers the following questions:

• How important are the overall survival data reported for CDK4/6 inhibitors at ESMO 2019 when managing your patients with HR+/HER2- advanced breast cancer?
• Results from the subgroup analyses from the CompLEEment-1 trial were presented. In your opinion, how useful are clinical factors for predicting response to CDK4/6 inhibitors?
• In your clinic, what are the roles of nurses and other staff when managing adverse events of CDK4/6 inhibitors?
• Combining CDK4/6 inhibitors with other targeted agents, such as HER2 inhibitors, are being investigated in clinical trials. In your opinion how valuable are these findings for the future management of patients with advanced breast cancer?
• Which data stood out for you at the ESMO 2019 and why? What are their implications for clinical practice in your region?

Prof. Wolfgang Janni is a full Professor and Director of the Department of Obstetrics and Gynaecology at the University of Ulm, Germany. He is a board-certified gynaecologist, with sub-specialties in gynaecological oncology, breast cancer, and perinatal medicine. In 2016, he was appointed as chair of the German Guideline Council for Breast Cancer (AGO), and in 2018 he was elected as a member of the National Academy of Science Leopoldina.

Prof. Janni’s research has received numerous international awards, including awards from the American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), and San Antonio Breast Cancer Symposium (SABCS). He is an editorial board member of several renowned peer-reviewed journals.

Prof. Wolfgang Janni discloses:  Honoraria and research grants from Amgen, AstraZeneca, Chugai, Genomic-Health, Lilly, Novartis, Pfizer and Roche.